Trials / Completed
CompletedNCT05299281
Micropulse Transscleral Diode Laser Cyclophotocoagulation (MP-TSCPC) as a Treatment Modality for Glaucoma Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Benha University · Academic / Other
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study objective was to evaluate the efficacy and safety of transscleral cyclophotocoagulation (TSCPC) using micropulse diode laser treatment in patients with various types of glaucoma.
Detailed description
Evaluation of the efficacy and safety of a new form of transscleral cyclophotocoagulation (TSCPC) using micropulse diode laser treatment in patients with various types of glaucoma. In this study, 810 nm infrared diode laser radiation in the micro- pulse mode was used in conjunction with a G probe (IRIDEX Medical Instruments, Mountain View, CA, USA). The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser set on micro- pulse mode, delivered over 100-200 seconds (envelope of micropulses) depending on severity of the case and other patient factors. With duty cycle 31.3% (This translates to 0.5 ms "on" time and 1.1 ms "off" time), which allows the tissue to cool down between laser shots, thus greatly reducing thermal damage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Micropulse transscleral cyclophotocoagulation (MP-TSCPC) | patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors. Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively. |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2021-07-01
- Completion
- 2021-07-01
- First posted
- 2022-03-29
- Last updated
- 2022-03-29
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05299281. Inclusion in this directory is not an endorsement.